Durect reports Q1 EPS (13c), consensus (12c)

Reports Q1 revenue $321,000, consensus $291.670. As of March 31 cash, cash equivalents and investments were $8.4M compared to cash, cash equivalents and investments of $12.0M at December 31, 2024. “Our primary focus continues to be initiating the Phase 3 trial of larsucosterol for severe AH, contingent on securing sufficient funding,” stated James E. Brown, President and CEO of DURECT (DRRX). “We continue to be engaged in active dialogue to explore all options for funding the continued development of larsucosterol, including potential business development and financing transactions. Additionally, the publication of the results of our Phase 2b AHFIRM trial in January in NEJM Evidence provides important validation of the potential value of larsucosterol as a treatment for AH and supports our planned Phase 3 trial design.”